MaÅ‚gorzata Zakrzewska

List of Publications by Year
in descending order

48 papers	1,101 citations	361413 20 h-index	434195 31 g-index
48 all docs	48 docs citations	48 times ranked	1400 citing authors

#	Article	IF	Citations
1	Targeting Cellular Trafficking of Fibroblast Growth Factor Receptors as a Strategy for Selective Cancer Treatment. Journal of Clinical Medicine, 2019, 8, 7.	2.4	66
2	Highly Stable Mutants of Human Fibroblast Growth Factor-1 Exhibit Prolonged Biological Action. Journal of Molecular Biology, 2005, 352, 860-875.	4.2	62
3	FGF-1: From Biology Through Engineering to Potential Medical Applications. Critical Reviews in Clinical Laboratory Sciences, 2008, 45, 91-135.	6.1	57
4	Phosphorylation of Fibroblast Growth Factor (FGF) Receptor 1 at Ser777 by p38 Mitogen-Activated Protein Kinase Regulates Translocation of Exogenous FGF1 to the Cytosol and Nucleus. Molecular and Cellular Biology, 2008, 28, 4129-4141.	2.3	53
5	Design of fully active FGF-1 variants with increased stability. Protein Engineering, Design and Selection, 2004, 17, 603-611.	2.1	51
6	Increased Protein Stability of FGF1 Can Compensate for Its Reduced Affinity for Heparin. Journal of Biological Chemistry, 2009, 284, 25388-25403.	3.4	48
7	Instability restricts signaling of multiple fibroblast growth factors. Cellular and Molecular Life Sciences, 2015, 72, 2445-2459.	5.4	48
8	Cross-Talk between Fibroblast Growth Factor Receptors and Other Cell Surface Proteins. Cells, 2019, 8, 455.	4.1	48
9	ERK-Mediated Phosphorylation of Fibroblast Growth Factor Receptor 1 on Ser ⁷⁷⁷ Inhibits Signaling. Science Signaling, 2013, 6, ra11.	3.6	40
10	Clathrin- and Dynamin-Independent Endocytosis of FGFR3 â€“ Implications for Signalling. PLoS ONE, 2011, 6, e21708.	2.5	35
11	High-Affinity Internalizing Human scFv-Fc Antibody for Targeting FGFR1-Overexpressing Lung Cancer. Molecular Cancer Research, 2017, 15, 1040-1050.	3.4	34
12	FGF/FGFR-Dependent Molecular Mechanisms Underlying Anti-Cancer Drug Resistance. Cancers, 2021, 13, 5796.	3.7	32
13	Differential regulation of fibroblast growth factor receptor 1 trafficking and function by extracellular galectins. Cell Communication and Signaling, 2019, 17, 65.	6.5	30
14	Efficient production and purification of extracellular domain of human FGFR-Fc fusion proteins from Chinese hamster ovary cells. Protein Expression and Purification, 2014, 99, 50-57.	1.3	29
15	Design and characteristics of cytotoxic fibroblast growth factor 1 conjugate for fibroblast growth factor receptor-targeted cancer therapy. Drug Design, Development and Therapy, 2016, Volume 10, 2547-2560.	4.3	27
16	Nanodiamonds as â€œartificial proteinsâ€• Regulation of a cell signalling system using low nanomolar solutions of inorganic nanocrystals. Biomaterials, 2018, 176, 106-121.	11.4	27
17	Translocation of Exogenous FGF1 and FGF2 Protects the Cell against Apoptosis Independently of Receptor Activation. Journal of Molecular Biology, 2018, 430, 4087-4101.	4.2	26
18	FHF1 is a bona fide fibroblast growth factor that activates cellular signaling in FGFR-dependent manner. Cell Communication and Signaling, 2020, 18, 69.	6.5	25

#	Article	IF	Citations
19	Antibody-induced dimerization of FGFR1 promotes receptor endocytosis independently of its kinase activity. Scientific Reports, 2017, 7, 7121.	3.3	23
20	FGF2 Dual Warhead Conjugate with Monomethyl Auristatin E and Î±-Amanitin Displays a Cytotoxic Effect towards Cancer Cells Overproducing FGF Receptor 1. International Journal of Molecular Sciences, 2018, 19, 2098.	4.1	22
21	Galectins as modulators of receptor tyrosine kinases signaling in health and disease. Cytokine and Growth Factor Reviews, 2021, 60, 89-106.	7.2	22
22	FGF1-gold nanoparticle conjugates targeting FGFR efficiently decrease cell viability upon NIR irradiation. International Journal of Nanomedicine, 2012, 7, 5915.	6.7	21
23	High Affinity Promotes Internalization of Engineered Antibodies Targeting FGFR1. International Journal of Molecular Sciences, 2018, 19, 1435.	4.1	21
24	Cytotoxic Conjugates of Fibroblast Growth Factor 2 (FGF2) with Monomethyl Auristatin E for Effective Killing of Cells Expressing FGF Receptors. ACS Omega, 2017, 2, 3792-3805.	3.5	20
25	High-Yield Site-Specific Conjugation of Fibroblast Growth Factor 1 with Monomethylauristatin E via Cysteine Flanked by Basic Residues. Bioconjugate Chemistry, 2017, 28, 1850-1858.	3.6	19
26	Nucleolin Regulates Phosphorylation and Nuclear Export of Fibroblast Growth Factor 1 (FGF1). PLoS ONE, 2014, 9, e90687.	2.5	18
27	Stable Fibroblast Growth Factor 2 Dimers with High Pro-Survival and Mitogenic Potential. International Journal of Molecular Sciences, 2020, 21, 4108.	4.1	18
28	Intracellular partners of fibroblast growth factors 1 and 2 - implications for functions. Cytokine and Growth Factor Reviews, 2021, 57, 93-111.	7.2	18
29	Crosstalk between p38 and Erk 1/2 in Downregulation of FGF1-Induced Signaling. International Journal of Molecular Sciences, 2019, 20, 1826.	4.1	15
30	Identification of new <scp>FGF</scp>1 binding partnersâ€"Implications for its intracellular function. IUBMB Life, 2016, 68, 242-251.	3.4	14
31	The cytotoxic conjugate of highly internalizing tetravalent antibody for targeting FGFR1-overproducing cancer cells. Molecular Medicine, 2021, 27, 46.	4.4	14
32	FGFR1 clustering with engineered tetravalent antibody improves the efficiency and modifies the mechanism of receptor internalization. Molecular Oncology, 2020, 14, 1998-2021.	4.6	13
33	Translocation of exogenous FGF1 into cytosol and nucleus is a periodic event independent of receptor kinase activity. Experimental Cell Research, 2011, 317, 1005-1015.	2.6	11
34	The autoinhibitory function of D1 domain of FGFR1 goes beyond the inhibition of ligand binding. International Journal of Biochemistry and Cell Biology, 2017, 89, 193-198.	2.8	10
35	Dissecting biological activities of fibroblast growth factor receptors by the coiled-coil-mediated oligomerization of FGF1. International Journal of Biological Macromolecules, 2021, 180, 470-483.	7.5	10
36	Roles of the FGF-FGFR Signaling System in Cancer Development and Inflammation. Cells, 2021, 10, 2231.	4.1	10

#	Article	IF	Citations
37	Low Stability of Integrin-Binding Deficient Mutant of FGF1 Restricts Its Biological Activity. Cells, 2019, 8, 899.	4.1	9
38	Structural Requirements of FGF-1 for Receptor Binding and Translocation into Cellsâ€. Biochemistry, 2006, 45, 15338-15348.	2.5	8
39	Site-Specific, Stoichiometric-Controlled, PEGylated Conjugates of Fibroblast Growth Factor 2 (FGF2) with Hydrophilic Auristatin Y for Highly Selective Killing of Cancer Cells Overproducing Fibroblast Growth Factor Receptor 1 (FGFR1). Molecular Pharmaceutics, 2020, 17, 2734-2748.	4.6	8
40	Specific Antibody Fragment Ligand Traps Blocking FGF1 Activity. International Journal of Molecular Sciences, 2018, 19, 2470.	4.1	7
41	Fibroblast Growth Factor 2 Conjugated with Monomethyl Auristatin E Inhibits Tumor Growth in a Mouse Model. Biomacromolecules, 2021, 22, 4169-4180.	5.4	7
42	Modular self-assembly system for development of oligomeric, highly internalizing and potent cytotoxic conjugates targeting fibroblast growth factor receptors. Journal of Biomedical Science, 2021, 28, 69.	7.0	7
43	Size Limitation in Translocation of Fibroblast Growth Factor 1 Fusion Proteins across the Endosomal Membrane. Biochemistry, 2009, 48, 7209-7218.	2.5	5
44	Intrinsically Fluorescent Oligomeric Cytotoxic Conjugates Toxic for FGFR1-Overproducing Cancers. Biomacromolecules, 2021, 22, 5349-5362.	5.4	5
45	FGF1 Fusions with the Fc Fragment of IgG1 for the Assembly of GFPpolygons-Mediated Multivalent Complexes Recognizing FGFRs. Biomolecules, 2021, 11, 1088.	4.0	3
46	Preparation of Site-Specific Cytotoxic Protein Conjugates via Maleimide-thiol Chemistry and Sortase A-Mediated Ligation. Journal of Visualized Experiments, 2021, , .	0.3	2
47	Tailoring Small Proteins Towards Biomedical Applications. Current Pharmaceutical Biotechnology, 2011, 12, 1792-1798.	1.6	2
48	Nuclear Localization Sequence of FGF1 Is Not Required for Its Intracellular Anti-Apoptotic Activity in Differentiated Cells. Cells, 2022, 11, 522.	4.1	1